[Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy 
in Postoperative Patients with Stage I Lung Adenocarcinoma].

Ke Zhao, Chao Guo, Yeye Chen, Shanqing Li
{"title":"[Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy \u2029in Postoperative Patients with Stage I Lung Adenocarcinoma].","authors":"Ke Zhao, Chao Guo, Yeye Chen, Shanqing Li","doi":"10.3779/j.issn.1009-3419.2024.101.26","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is one of the main causes of cancer burden and death in China, with nearly 800,000 newly diagnosed lung cancer patients each year, nearly half of whom are lung adenocarcinoma (LUAD) patients. According to current clinical guidelines, surgery is the main treatment for stage I LUAD patients, but the 5-year overall survival rate of stage I LUAD patients alone is still unsatisfactory, about 73%-90%, indicating that a considerable number of patients require other means to improve survival benefits. Chemotherapy and targeted therapy have achieved great success in the treatment of locally advanced and metastatic LUAD patients, but there is still controversy over whether they can benefit stage I LUAD postoperative patients. Under the circumstances, many researchers have paid attention to this issue and made beneficial explorations. This review provides a brief review of the factors that affect the acceptance of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, as well as the relevant clinical research on the application of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, in order to gain a broader understanding of the latest developments in this field and find new breakthroughs to promote sustained research in this field.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"777-784"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629094/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.101.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer is one of the main causes of cancer burden and death in China, with nearly 800,000 newly diagnosed lung cancer patients each year, nearly half of whom are lung adenocarcinoma (LUAD) patients. According to current clinical guidelines, surgery is the main treatment for stage I LUAD patients, but the 5-year overall survival rate of stage I LUAD patients alone is still unsatisfactory, about 73%-90%, indicating that a considerable number of patients require other means to improve survival benefits. Chemotherapy and targeted therapy have achieved great success in the treatment of locally advanced and metastatic LUAD patients, but there is still controversy over whether they can benefit stage I LUAD postoperative patients. Under the circumstances, many researchers have paid attention to this issue and made beneficial explorations. This review provides a brief review of the factors that affect the acceptance of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, as well as the relevant clinical research on the application of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, in order to gain a broader understanding of the latest developments in this field and find new breakthroughs to promote sustained research in this field.
.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[辅助化疗和靶向治疗在I期肺腺癌术后患者中的应用进展
]。
肺癌是中国癌症负担和死亡的主要原因之一,每年有近80万新诊断的肺癌患者,其中近一半是肺腺癌(LUAD)患者。根据目前的临床指南,手术是I期LUAD患者的主要治疗方法,但I期LUAD患者单独的5年总生存率仍不理想,约为73%-90%,这表明相当多的患者需要其他手段来提高生存效益。化疗和靶向治疗在局部晚期和转移性LUAD患者的治疗中取得了巨大的成功,但是否能使I期LUAD术后患者受益仍存在争议。在这种情况下,许多研究者开始关注这一问题,并进行了有益的探索。本文就影响I期LUAD术后患者接受辅助化疗和靶向治疗的因素,以及辅助化疗和靶向治疗在I期LUAD术后患者中的应用的相关临床研究进行简要综述,以期更广泛地了解该领域的最新进展,寻找新的突破,促进该领域的持续研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
The Lean Startup in Science
IF 0 SSRN Electronic JournalPub Date : 2023-01-01 DOI: 10.2139/ssrn.4511677
Matthew Halma
Polis University as Lean Startup Innovation
IF 0 International journal of business researchPub Date : 2015-04-25 DOI: 10.5539/IBR.V8N5P19
P. Nientied
来源期刊
中国肺癌杂志
中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
0.00%
发文量
5131
审稿时长
14 weeks
期刊介绍: Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.
期刊最新文献
[A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified 
Lung Squamous Cell Carcinoma and Literature Review]. [Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]. [Application of Nano-drug Delivery Technology in Overcoming Drug Resistance 
in Lung Cancer]. [Clinicopathological Analysis of 14 Cases of Primary Pulmonary Lymphoepithelial Carcinoma]. [Immunotherapy for Extensive-stage Small Cell Lung Cancer: 
Research Progress and Future Perspectives].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1